Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence

Use of COVID-19 Convalescent Plasma for Treatment of Symptomatic SARS-CoV-2 Infection at a Children's Hospital: A Contribution to a Still Inadequate Body of Evidence

Data on COVID-19 convalescent plasma (CCP) safety and efficacy in children and young adults are limited. This single-center prospective, open-label trial evaluates CCP safety, neutralizing antibody kinetics, and outcomes in children and young adults with moderate/severe COVID-19 (April 2020-March 20...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Children (Basel) 2023-02, Vol.10 (2), p.350
Hauptverfasser: Arrieta, Antonio, Galvis, Alvaro E, Osborne, Stephanie, Morphew, Tricia, Imfeld, Karen, Enriquez, Claudia, Hoang, Janet, Swearingen, Marcia, Nieves, Delma J, Ashouri, Negar, Singh, Jasjit, Nugent, Diane
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies
Antiviral drugs
Blood banks
Children
convalescent plasma
COVID-19
COVID-19 treatment
Diseases
Hospitalization
Kinetics
Laboratories
Patients
Pediatrics
Plasma
Proteins
Severe acute respiratory syndrome coronavirus 2
symptomatic SARS-CoV-2
Young adults
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Data on COVID-19 convalescent plasma (CCP) safety and efficacy in children and young adults are limited. This single-center prospective, open-label trial evaluates CCP safety, neutralizing antibody kinetics, and outcomes in children and young adults with moderate/severe COVID-19 (April 2020-March 2021). A total of 46 subjects received CCP; 43 were included in the safety analysis (SAS); 7.0% < 2 years old, 2.3% 2-
ISSN:2227-9067
2227-9067
DOI:10.3390/children10020350